Compositions and methods for treating neurological diseases or injury
US-2015320702-A1 · Nov 12, 2015 · US
Compounds for the treatment of neurological or mitochondrial diseases
US11771685B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11771685-B2 |
| Application number | US-201917264714-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 29, 2019 |
| Priority date | Jul 29, 2018 |
| Publication date | Oct 3, 2023 |
| Grant date | Oct 3, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compounds and methods are provided for the treatment of neurological or mitochondrial diseases, including epilepsy. In some embodiments, the compounds are substituted 1,4-naphthoquinones.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating epilepsy in a mammalian subject comprising administering to a subject a therapeutically effective dose of a pharmaceutical composition comprising a compound of the formula: or a pharmaceutically acceptable salt thereof. 2. The method of claim 1 , wherein the epilepsy is medication-resistant epilepsy. 3. The method of claim 1 , wherein the pharmaceutical composition is administered orally, sublingually, intranasally, intravenously, subcutaneously, parenterally, via inhalation or aerosol or the subject is a human. 4. The method of claim 1 , wherein the compound is further defined as: 5. The method of claim 1 , wherein the compound is formulated with a pharmaceutically acceptable excipient.
Assignees
Inventors
Classifications
- A61K31/4406Primary
only substituted in position 3, e.g. zimeldine (nicotinic acid A61K31/455) · CPC title
- A61K31/136Primary
having the amino group directly attached to the aromatic ring, e.g. benzeneamine · CPC title
- A61K31/18Primary
Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63) · CPC title
Antiepileptics; Anticonvulsants · CPC title
having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11771685B2 cover?
- Compounds and methods are provided for the treatment of neurological or mitochondrial diseases, including epilepsy. In some embodiments, the compounds are substituted 1,4-naphthoquinones.
- Who is the assignee on this patent?
- Musc Found For Res Dev
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4406. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).